Abstract
This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
CNS & Neurological Disorders - Drug Targets
Title:Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
Volume: 20
Author(s): Mostafa Mohammadi*
Affiliation:
- Islamic Azad University of Central Tehran Branch, Department of Electrical Engineering, Tehran,Iran
Abstract: This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Export Options
About this article
Cite this article as:
Mohammadi Mostafa*, Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients, CNS & Neurological Disorders - Drug Targets 2021; 20 () . https://dx.doi.org/10.2174/1871527320666210129121701
DOI https://dx.doi.org/10.2174/1871527320666210129121701 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry Therapeutic Potential of Citronella Essential Oil: A Review
Current Drug Discovery Technologies Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis
Current Neurovascular Research Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Adenosine Metabolism in Toxoplasma gondii: Potential Targets for Chemotherapy
Current Pharmaceutical Design Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling
Current Drug Targets <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research